25 XP   0   0   10

BridgeBio Pharma Inc
Buy, Hold or Sell?

Let's analyse Bridgebio together

PenkeI guess you are interested in BridgeBio Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BridgeBio Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BridgeBio Pharma Inc

I send you an email if I find something interesting about BridgeBio Pharma Inc.

Quick analysis of Bridgebio (30 sec.)










What can you expect buying and holding a share of Bridgebio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
14.3%

What is your share worth?

Current worth
$-7.28
Expected worth in 1 year
$-7.81
How sure are you?
23.8%

+ What do you gain per year?

Total Gains per Share
$-0.53
Return On Investment
-1.7%

For what price can you sell your share?

Current Price per Share
$30.92
Expected price per share
$23.67 - $40.65
How sure are you?
50%

1. Valuation of Bridgebio (5 min.)




Live pricePrice per Share (EOD)

$30.92

Intrinsic Value Per Share

$-27.19 - $-31.57

Total Value Per Share

$-34.47 - $-38.84

2. Growth of Bridgebio (5 min.)




Is Bridgebio growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.3b-$1.1b-$167.1m-13.1%

How much money is Bridgebio making?

Current yearPrevious yearGrowGrow %
Making money-$169.9m-$122.9m-$47m-27.7%
Net Profit Margin-8,317.4%-16,683.5%--

How much money comes from the company's main activities?

3. Financial Health of Bridgebio (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1031 / 1031

Most Revenue
#425 / 1031

Most Profit
#1019 / 1031

Most Efficient
#944 / 1031

What can you expect buying and holding a share of Bridgebio? (5 min.)

Welcome investor! Bridgebio's management wants to use your money to grow the business. In return you get a share of Bridgebio.

What can you expect buying and holding a share of Bridgebio?

First you should know what it really means to hold a share of Bridgebio. And how you can make/lose money.

Speculation

The Price per Share of Bridgebio is $30.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bridgebio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bridgebio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-7.28. Based on the TTM, the Book Value Change Per Share is $-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bridgebio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.91-2.9%-0.87-2.8%-0.65-2.1%-0.65-2.1%-0.63-2.0%
Usd Book Value Change Per Share-0.81-2.6%-0.13-0.4%-0.51-1.7%-0.34-1.1%-0.35-1.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.030.1%0.030.1%
Usd Total Gains Per Share-0.81-2.6%-0.13-0.4%-0.51-1.7%-0.31-1.0%-0.32-1.0%
Usd Price Per Share40.37-25.13-9.20-28.86-27.48-
Price to Earnings Ratio-11.07--7.10--12.69--13.57--12.93-
Price-to-Total Gains Ratio-50.04-13.88-6.59--47.12--47.12-
Price to Book Ratio-5.55--3.62--1.55-4.80-4.57-
Price-to-Total Gains Ratio-50.04-13.88-6.59--47.12--47.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.92
Number of shares32
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.13-0.34
Usd Total Gains Per Share-0.13-0.31
Gains per Quarter (32 shares)-4.23-9.79
Gains per Year (32 shares)-16.93-39.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-17-274-43-49
20-34-448-86-88
30-51-6112-129-127
40-68-7816-172-166
50-85-9520-215-205
60-102-11223-258-244
70-119-12927-301-283
80-135-14631-344-322
90-152-16335-388-361
100-169-18039-431-400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%5.016.00.023.8%5.016.00.023.8%
Dividend per Share0.00.04.00.0%1.00.011.08.3%3.00.017.015.0%3.00.018.014.3%3.00.018.014.3%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%5.016.00.023.8%5.016.00.023.8%

Fundamentals of Bridgebio

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Fundamental data was last updated by Penke on 2024-03-20 11:09:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BridgeBio Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bridgebio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • A Net Profit Margin of -9,636.0% means that $-96.36 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BridgeBio Pharma Inc:

  • The MRQ is -9,636.0%. The company is making a huge loss. -2
  • The TTM is -8,317.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-9,636.0%TTM-8,317.4%-1,318.6%
TTM-8,317.4%YOY-16,683.5%+8,366.2%
TTM-8,317.4%5Y-12,223.3%+3,905.9%
5Y-12,223.3%10Y-11,641.3%-582.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9,636.0%-159.2%-9,476.8%
TTM-8,317.4%-202.3%-8,115.1%
YOY-16,683.5%-263.0%-16,420.5%
5Y-12,223.3%-452.4%-11,770.9%
10Y-11,641.3%-589.0%-11,052.3%
1.1.2. Return on Assets

Shows how efficient Bridgebio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • -30.8% Return on Assets means that Bridgebio generated $-0.31 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BridgeBio Pharma Inc:

  • The MRQ is -30.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -29.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.8%TTM-29.4%-1.4%
TTM-29.4%YOY-17.2%-12.1%
TTM-29.4%5Y-17.8%-11.6%
5Y-17.8%10Y-17.3%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.8%-12.5%-18.3%
TTM-29.4%-12.2%-17.2%
YOY-17.2%-11.2%-6.0%
5Y-17.8%-13.3%-4.5%
10Y-17.3%-14.6%-2.7%
1.1.3. Return on Equity

Shows how efficient Bridgebio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • 0.0% Return on Equity means Bridgebio generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BridgeBio Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-20.1%+20.1%
5Y-20.1%10Y-19.2%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.0%+16.0%
TTM--15.8%+15.8%
YOY--13.9%+13.9%
5Y-20.1%-18.2%-1.9%
10Y-19.2%-19.1%-0.1%

1.2. Operating Efficiency of BridgeBio Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bridgebio is operating .

  • Measures how much profit Bridgebio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • An Operating Margin of -9,788.8% means the company generated $-97.89  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BridgeBio Pharma Inc:

  • The MRQ is -9,788.8%. The company is operating very inefficient. -2
  • The TTM is -7,228.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-9,788.8%TTM-7,228.9%-2,559.9%
TTM-7,228.9%YOY-13,403.4%+6,174.5%
TTM-7,228.9%5Y-11,630.9%+4,402.0%
5Y-11,630.9%10Y-11,077.0%-553.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9,788.8%-299.5%-9,489.3%
TTM-7,228.9%-208.5%-7,020.4%
YOY-13,403.4%-280.2%-13,123.2%
5Y-11,630.9%-459.9%-11,171.0%
10Y-11,077.0%-596.9%-10,480.1%
1.2.2. Operating Ratio

Measures how efficient Bridgebio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 102.24 means that the operating costs are $102.24 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BridgeBio Pharma Inc:

  • The MRQ is 102.239. The company is inefficient in keeping operating costs low. -1
  • The TTM is 74.658. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ102.239TTM74.658+27.581
TTM74.658YOY131.655-56.997
TTM74.6585Y117.460-42.802
5Y117.46010Y111.867+5.593
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ102.2392.817+99.422
TTM74.6583.181+71.477
YOY131.6553.609+128.046
5Y117.4605.554+111.906
10Y111.8677.396+104.471

1.3. Liquidity of BridgeBio Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bridgebio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.32 means the company has $3.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BridgeBio Pharma Inc:

  • The MRQ is 3.320. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.430. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.320TTM4.430-1.110
TTM4.430YOY5.516-1.086
TTM4.4305Y7.801-3.371
5Y7.80110Y8.080-0.279
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3203.987-0.667
TTM4.4304.440-0.010
YOY5.5165.569-0.053
5Y7.8016.158+1.643
10Y8.0806.492+1.588
1.3.2. Quick Ratio

Measures if Bridgebio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • A Quick Ratio of 3.45 means the company can pay off $3.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BridgeBio Pharma Inc:

  • The MRQ is 3.445. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.102. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.445TTM5.102-1.657
TTM5.102YOY6.784-1.682
TTM5.1025Y9.769-4.666
5Y9.76910Y9.941-0.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4453.653-0.208
TTM5.1024.158+0.944
YOY6.7845.515+1.269
5Y9.7696.012+3.757
10Y9.9416.206+3.735

1.4. Solvency of BridgeBio Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bridgebio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bridgebio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.46 means that Bridgebio assets are financed with 345.7% credit (debt) and the remaining percentage (100% - 345.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BridgeBio Pharma Inc:

  • The MRQ is 3.457. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.225. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.457TTM3.225+0.232
TTM3.225YOY2.502+0.723
TTM3.2255Y1.735+1.490
5Y1.73510Y1.711+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4570.336+3.121
TTM3.2250.330+2.895
YOY2.5020.267+2.235
5Y1.7350.367+1.368
10Y1.7110.378+1.333
1.4.2. Debt to Equity Ratio

Measures if Bridgebio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bridgebio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BridgeBio Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.917-0.917
5Y0.91710Y0.874+0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY-0.334-0.334
5Y0.9170.431+0.486
10Y0.8740.476+0.398

2. Market Valuation of BridgeBio Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bridgebio generates.

  • Above 15 is considered overpriced but always compare Bridgebio to the Biotechnology industry mean.
  • A PE ratio of -11.07 means the investor is paying $-11.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BridgeBio Pharma Inc:

  • The EOD is -8.480. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.071. Based on the earnings, the company is expensive. -2
  • The TTM is -7.105. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.480MRQ-11.071+2.592
MRQ-11.071TTM-7.105-3.966
TTM-7.105YOY-12.689+5.584
TTM-7.1055Y-13.574+6.469
5Y-13.57410Y-12.928-0.646
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.480-2.697-5.783
MRQ-11.071-2.422-8.649
TTM-7.105-2.709-4.396
YOY-12.689-4.116-8.573
5Y-13.574-6.257-7.317
10Y-12.928-6.478-6.450
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BridgeBio Pharma Inc:

  • The EOD is -11.383. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.862. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.870. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.383MRQ-14.862+3.479
MRQ-14.862TTM-8.870-5.993
TTM-8.870YOY-5.549-3.321
TTM-8.8705Y-13.106+4.236
5Y-13.10610Y-12.482-0.624
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.383-3.344-8.039
MRQ-14.862-2.939-11.923
TTM-8.870-3.486-5.384
YOY-5.549-5.592+0.043
5Y-13.106-8.464-4.642
10Y-12.482-8.872-3.610
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bridgebio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -5.55 means the investor is paying $-5.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BridgeBio Pharma Inc:

  • The EOD is -4.248. Based on the equity, the company is expensive. -2
  • The MRQ is -5.546. Based on the equity, the company is expensive. -2
  • The TTM is -3.623. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.248MRQ-5.546+1.298
MRQ-5.546TTM-3.623-1.924
TTM-3.623YOY-1.550-2.073
TTM-3.6235Y4.803-8.426
5Y4.80310Y4.574+0.229
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.2482.198-6.446
MRQ-5.5462.042-7.588
TTM-3.6232.121-5.744
YOY-1.5502.907-4.457
5Y4.8033.682+1.121
10Y4.5744.114+0.460
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BridgeBio Pharma Inc.

3.1. Institutions holding BridgeBio Pharma Inc

Institutions are holding 91.931% of the shares of BridgeBio Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Kohlberg Kravis Roberts & Co LP17.665237.05523106097100
2023-12-31Viking Global Investors LP14.2873.71462512099100
2023-12-31Vanguard Group Inc7.27990.011312800294152431313.5182
2023-12-31BlackRock Inc5.77640.0105101567739068309.8036
2023-12-31Goldman Sachs Group Inc3.71560.023765332705108113358.4246
2023-12-31Aisling Capital Management LP3.451173.0736606812500
2023-09-30LAURION CAPITAL MANAGEMENT LP3.21390.909565103990169618.9857
2023-12-31State Street Corporation2.89310.015086899464850.9222
2023-12-31Cormorant Asset Management, LLC1.90196.44763344179-1318351-28.2754
2023-12-31Lord, Abbett & Co LLC1.7620.449130980822303681289.9897
2023-12-31Pictet Asset Manangement SA1.57380.12322767185271630.9913
2023-12-31Geode Capital Management, LLC1.54360.011527141682029888.0834
2023-12-31AllianceBernstein L.P.1.45450.03972557416-158724-5.8437
2023-12-31FMR Inc1.37310.00752414341-13181-0.543
2023-12-31SC US (TTGP), LTD.1.0580.6195186036400
2023-12-31Perceptive Advisors LLC0.99471.576174893300
2023-12-31Morgan Stanley - Brokerage Accounts0.9440.0059165978221172214.6211
2023-12-31Citigroup Inc0.88560.04431557231-30361-1.9124
2023-12-31Wellington Management Company LLP0.85030.01131495114755645.3231
2023-12-31T. Rowe Price Investment Management,Inc.0.81630.0377143528043964844.1577
Total 73.44124.1812129130437+10227586+7.9%

3.2. Funds holding BridgeBio Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.34790.00914128409-10653-0.2574
2024-02-29Vanguard Small Cap Index1.91250.08173362708312140.9369
2024-02-29iShares Russell 2000 ETF1.57640.15182771756-453-0.0163
2024-02-29SPDR® S&P Biotech ETF1.47571.1192594800484801.9039
2024-02-29Vanguard Small Cap Value Index Inv1.13280.1279199179484590.4265
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.08440.06381906734-1354-0.071
2023-12-31Lord Abbett & Co. Growth Equity- SA0.81681.0628143620614362060
2024-01-31Lord Abbett Growth Leaders I0.81310.86061429666-6540-0.4554
2023-12-31Fidelity Small Cap Index0.64730.18081138131142481.2677
2024-01-31Lord Abbett Developing Growth A0.64581.68381135537-14423-1.2542
2024-01-31Fidelity Select Biotechnology0.64130.83811127546-127800-10.1805
2023-10-31Pictet-Biotech P USD0.5842.0919102694225101632.3505
2023-11-30MEDICAL BioHealth EUR Acc0.56554.4499438000
2023-12-31American Funds SMALLCAP World A0.54920.054296565300
2024-02-29iShares Biotechnology ETF0.54340.429955532-4300-0.448
2024-01-31AB Small Cap Growth A0.44840.7312788441-58840-6.9446
2024-01-31Fidelity Extended Market Index0.40960.069720161108011.5226
2023-12-31Eventide Healthcare & Life Sciences I0.40771.736471692700
2024-02-29iShares Russell 2000 Growth ETF0.39860.2108700854-815-0.1162
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.39570.0569695848213003.1577
Total 17.396115.998830588025+1596546+5.2%

3.3. Insider Transactions

Insiders are holding 5.369% of the shares of BridgeBio Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-01Randal W ScottSELL250034
2024-01-16Hannah ValantineSELL291537.97
2023-12-26Frank MccormickSELL10000042.06
2023-12-18Randal W ScottSELL200040
2023-08-17Brian C StephensonSELL2268328.59
2023-08-17Neil KumarSELL5155228.59
2023-07-18Global Investors Lp VikingSELL150000035
2023-05-17Brian C StephensonSELL2442414.01
2023-05-17Neil KumarSELL5155214.01
2023-04-05Brian C StephensonSELL5550015.45
2023-04-05Neil KumarSELL12000015.46

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BridgeBio Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.807-0.132-84%-0.514-36%-0.336-58%-0.347-57%
Book Value Per Share---7.279-6.912-5%-6.006-17%-2.664-63%-2.563-65%
Current Ratio--3.3204.430-25%5.516-40%7.801-57%8.080-59%
Debt To Asset Ratio--3.4573.225+7%2.502+38%1.735+99%1.711+102%
Debt To Equity Ratio----0%-0%0.917-100%0.874-100%
Dividend Per Share----0%-0%0.031-100%0.029-100%
Eps---0.912-0.872-4%-0.652-28%-0.650-29%-0.629-31%
Free Cash Flow Per Share---0.679-0.717+6%-0.577-15%-0.587-13%-0.572-16%
Free Cash Flow To Equity Per Share---0.704-0.105-85%-0.595-15%-0.040-94%0.021-3470%
Gross Profit Margin--1.0001.0000%1.0000%1.0030%1.0030%
Intrinsic Value_10Y_max---31.565--------
Intrinsic Value_10Y_min---27.187--------
Intrinsic Value_1Y_max---2.782--------
Intrinsic Value_1Y_min---2.732--------
Intrinsic Value_3Y_max---8.648--------
Intrinsic Value_3Y_min---8.251--------
Intrinsic Value_5Y_max---14.866--------
Intrinsic Value_5Y_min---13.773--------
Market Cap5703255840.000-31%7446327240.0004635278760.000+61%1696497270.000+339%5322823590.000+40%5069355800.000+47%
Net Profit Margin---96.360-83.174-14%-166.835+73%-122.233+27%-116.413+21%
Operating Margin---97.888-72.289-26%-134.034+37%-116.309+19%-110.770+13%
Operating Ratio--102.23974.658+37%131.655-22%117.460-13%111.867-9%
Pb Ratio-4.248+23%-5.546-3.623-35%-1.550-72%4.803-215%4.574-221%
Pe Ratio-8.480+23%-11.071-7.105-36%-12.689+15%-13.574+23%-12.928+17%
Price Per Share30.920-31%40.37025.130+61%9.198+339%28.858+40%27.483+47%
Price To Free Cash Flow Ratio-11.383+23%-14.862-8.870-40%-5.549-63%-13.106-12%-12.482-16%
Price To Total Gains Ratio-38.328+23%-50.04313.876-461%6.595-859%-47.117-6%-47.117-6%
Quick Ratio--3.4455.102-32%6.784-49%9.769-65%9.941-65%
Return On Assets---0.308-0.294-5%-0.172-44%-0.178-42%-0.173-44%
Return On Equity----0%-0%-0.2010%-0.1920%
Total Gains Per Share---0.807-0.132-84%-0.514-36%-0.306-62%-0.317-61%
Usd Book Value---1342535000.000-1274880250.000-5%-1107749250.000-17%-491324150.000-63%-472761238.095-65%
Usd Book Value Change Per Share---0.807-0.132-84%-0.514-36%-0.336-58%-0.347-57%
Usd Book Value Per Share---7.279-6.912-5%-6.006-17%-2.664-63%-2.563-65%
Usd Dividend Per Share----0%-0%0.031-100%0.029-100%
Usd Eps---0.912-0.872-4%-0.652-28%-0.650-29%-0.629-31%
Usd Free Cash Flow---125254000.000-132256500.000+6%-106453750.000-15%-108348900.000-13%-105434904.762-16%
Usd Free Cash Flow Per Share---0.679-0.717+6%-0.577-15%-0.587-13%-0.572-16%
Usd Free Cash Flow To Equity Per Share---0.704-0.105-85%-0.595-15%-0.040-94%0.021-3470%
Usd Market Cap5703255840.000-31%7446327240.0004635278760.000+61%1696497270.000+339%5322823590.000+40%5069355800.000+47%
Usd Price Per Share30.920-31%40.37025.130+61%9.198+339%28.858+40%27.483+47%
Usd Profit---168148000.000-169973000.000+1%-122933750.000-27%-122170400.000-27%-118192809.524-30%
Usd Revenue--1745000.0002325750.000-25%19412000.000-91%10964750.000-84%10442619.048-83%
Usd Total Gains Per Share---0.807-0.132-84%-0.514-36%-0.306-62%-0.317-61%
 EOD+2 -6MRQTTM+10 -21YOY+8 -235Y+9 -2610Y+9 -26

4.2. Fundamental Score

Let's check the fundamental score of BridgeBio Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.480
Price to Book Ratio (EOD)Between0-1-4.248
Net Profit Margin (MRQ)Greater than0-96.360
Operating Margin (MRQ)Greater than0-97.888
Quick Ratio (MRQ)Greater than13.445
Current Ratio (MRQ)Greater than13.320
Debt to Asset Ratio (MRQ)Less than13.457
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.308
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of BridgeBio Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.752
Ma 20Greater thanMa 5029.555
Ma 50Greater thanMa 10033.016
Ma 100Greater thanMa 20033.558
OpenGreater thanClose30.780
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net -18,3821,813-16,56914,514-2,055-17,252-19,30740,33121,024



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets546,380
Total Liabilities1,888,915
Total Stockholder Equity-1,354,257
 As reported
Total Liabilities 1,888,915
Total Stockholder Equity+ -1,354,257
Total Assets = 546,380

Assets

Total Assets546,380
Total Current Assets477,593
Long-term Assets68,787
Total Current Assets
Cash And Cash Equivalents 375,935
Short-term Investments 58,949
Net Receivables 1,751
Inventory 16,653
Other Current Assets 24,305
Total Current Assets  (as reported)477,593
Total Current Assets  (calculated)477,593
+/-0
Long-term Assets
Property Plant Equipment 19,843
Intangible Assets 26,319
Long-term Assets Other 22,625
Long-term Assets  (as reported)68,787
Long-term Assets  (calculated)68,787
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities143,844
Long-term Liabilities1,745,071
Total Stockholder Equity-1,354,257
Total Current Liabilities
Short-term Debt 4,128
Accounts payable 10,655
Other Current Liabilities 122,965
Total Current Liabilities  (as reported)143,844
Total Current Liabilities  (calculated)137,748
+/- 6,096
Long-term Liabilities
Long term Debt 1,726,729
Capital Lease Obligations Min Short Term Debt8,981
Long-term Liabilities Other 9,361
Long-term Liabilities  (as reported)1,745,071
Long-term Liabilities  (calculated)1,745,071
+/-0
Total Stockholder Equity
Common Stock181
Retained Earnings -2,560,501
Accumulated Other Comprehensive Income 31
Other Stockholders Equity 1,206,032
Total Stockholder Equity (as reported)-1,354,257
Total Stockholder Equity (calculated)-1,354,257
+/-0
Other
Capital Stock181
Cash and Short Term Investments 434,884
Common Stock Shares Outstanding 174,462
Current Deferred Revenue6,096
Liabilities and Stockholders Equity 546,380
Net Debt 1,363,903
Net Invested Capital 372,472
Net Working Capital 333,749
Property Plant and Equipment Gross 19,843
Short Long Term Debt Total 1,739,838



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
464,941
401,374
325,540
640,530
631,679
989,799
905,227
787,693
703,588
1,093,308
1,081,486
781,524
1,012,792
813,149
862,233
728,740
623,036
625,680
503,661
655,008
546,380
546,380655,008503,661625,680623,036728,740862,233813,1491,012,792781,5241,081,4861,093,308703,588787,693905,227989,799631,679640,530325,540401,374464,941000
   > Total Current Assets 
0
0
0
445,223
382,473
306,709
558,155
599,766
948,167
861,935
745,384
642,824
945,114
970,559
639,710
839,710
716,230
771,280
642,219
505,200
502,899
382,397
549,618
477,593
477,593549,618382,397502,899505,200642,219771,280716,230839,710639,710970,559945,114642,824745,384861,935948,167599,766558,155306,709382,473445,223000
       Cash And Cash Equivalents 
0
0
0
436,086
373,027
293,803
413,973
363,773
757,049
540,919
366,967
356,082
471,176
378,420
180,347
393,772
371,550
470,098
483,235
376,689
407,368
302,438
505,213
375,935
375,935505,213302,438407,368376,689483,235470,098371,550393,772180,347378,420471,176356,082366,967540,919757,049363,773413,973293,803373,027436,086000
       Short-term Investments 
0
0
0
0
0
0
122,080
182,220
148,126
300,020
343,714
251,011
447,942
459,243
419,264
442,891
299,676
245,607
108,742
95,233
34,122
333,307
38,052
58,949
58,94938,052333,30734,12295,233108,742245,607299,676442,891419,264459,243447,942251,011343,714300,020148,126182,220122,080000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
8,000
0
462
44,325
8,172
19,749
10,983
22,821
24,581
17,079
10,761
8,614
5,170
1,751
1,7515,1708,61410,76117,07924,58122,82110,98319,7498,17244,32546208,0000000000000
       Other Current Assets 
0
0
0
2,050
2,276
5,374
13,352
22,629
19,782
20,996
26,703
35,731
25,534
26,670
31,927
32,446
34,021
32,754
25,661
21,922
25,145
20,546
22,583
24,305
24,30522,58320,54625,14521,92225,66132,75434,02132,44631,92726,67025,53435,73126,70320,99619,78222,62913,3525,3742,2762,050000
   > Long-term Assets 
0
0
0
19,718
18,901
18,831
82,375
31,913
41,632
43,292
42,309
60,764
148,194
110,927
141,814
173,082
96,919
90,953
86,521
117,836
122,781
121,264
105,390
68,787
68,787105,390121,264122,781117,83686,52190,95396,919173,082141,814110,927148,19460,76442,30943,29241,63231,91382,37518,83118,90119,718000
       Property Plant Equipment 
0
0
0
1,575
1,882
1,865
2,984
5,625
24,610
26,038
25,826
36,833
35,813
42,236
44,849
45,973
31,118
29,723
27,341
25,247
24,098
22,861
21,745
19,843
19,84321,74522,86124,09825,24727,34129,72331,11845,97344,84942,23635,81336,83325,82626,03824,6105,6252,9841,8651,8821,575000
       Long Term Investments 
0
0
0
0
12,452
7,495
76,793
31,144
23,210
0
0
0
82,202
79,582
17,707
49,148
0
0
0
43,653
49,803
50,487
38,052
0
038,05250,48749,80343,65300049,14817,70779,58282,20200023,21031,14476,7937,49512,4520000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,204
44,934
30,476
29,908
29,310
28,712
28,113
27,515
26,917
26,319
26,31926,91727,51528,11328,71229,31029,90830,47644,93446,20400000000000000
       Other Assets 
0
0
0
0
4,567
9,471
2,598
26,288
17,022
17,254
16,483
23,931
30,179
49,797
33,054
33,027
35,325
114,038
113,774
140,808
0
119,978
0
0
00119,9780140,808113,774114,03835,32533,02733,05449,79730,17923,93116,48317,25417,02226,2882,5989,4714,5670000
> Total Liabilities 
0
0
0
566,444
90,713
593,093
116,263
155,703
537,728
577,715
569,306
595,702
1,481,402
1,537,111
1,517,398
1,878,371
1,853,836
1,877,246
1,859,113
1,867,960
1,839,293
1,853,299
1,848,743
1,888,915
1,888,9151,848,7431,853,2991,839,2931,867,9601,859,1131,877,2461,853,8361,878,3711,517,3981,537,1111,481,402595,702569,306577,715537,728155,703116,263593,09390,713566,444000
   > Total Current Liabilities 
0
0
0
32,577
35,472
38,705
39,858
52,385
62,404
92,640
75,707
91,853
94,729
127,369
95,823
130,131
103,463
141,160
119,194
117,753
92,922
106,344
101,928
143,844
143,844101,928106,34492,922117,753119,194141,160103,463130,13195,823127,36994,72991,85375,70792,64062,40452,38539,85838,70535,47232,577000
       Short-term Debt 
0
0
0
0
0
0
0
8,000
2,510
3,627
3,617
1,458
7,453
4,540
4,999
4,938
4,363
4,310
4,044
3,675
3,674
3,776
4,137
4,128
4,1284,1373,7763,6743,6754,0444,3104,3634,9384,9994,5407,4531,4583,6173,6272,5108,0000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
1,458
3,646
0
0
0
0
0
0
0
0
0
0
0
000000000003,6461,45800000000000
       Accounts payable 
0
0
0
13,509
12,344
16,065
10,270
8,852
13,086
12,835
9,839
8,945
10,340
22,329
12,035
11,884
10,107
8,793
10,158
11,558
4,076
3,874
4,472
10,655
10,6554,4723,8744,07611,55810,1588,79310,10711,88412,03522,32910,3408,9459,83912,83513,0868,85210,27016,06512,34413,509000
       Other Current Liabilities 
0
0
0
19,068
23,128
22,640
29,588
4,078
3,539
5,276
5,198
5,550
76,936
105,040
78,789
113,309
88,993
120,867
97,474
94,364
78,497
92,484
86,727
122,965
122,96586,72792,48478,49794,36497,474120,86788,993113,30978,789105,04076,9365,5505,1985,2763,5394,07829,58822,64023,12819,068000
   > Long-term Liabilities 
0
0
0
533,867
55,241
554,388
76,405
103,318
475,324
485,075
493,599
503,849
1,386,673
1,409,742
1,421,575
1,748,240
1,750,373
1,736,086
1,739,919
1,750,207
1,746,371
1,746,955
1,746,815
1,745,071
1,745,0711,746,8151,746,9551,746,3711,750,2071,739,9191,736,0861,750,3731,748,2401,421,5751,409,7421,386,673503,849493,599485,075475,324103,31876,405554,38855,241533,867000
       Long term Debt Total 
0
0
0
0
54,861
74,997
75,017
91,791
461,339
0
0
475,857
1,361,199
1,373,915
1,375,314
1,703,805
1,708,050
1,693,179
1,698,693
1,707,615
1,713,292
0
0
0
0001,713,2921,707,6151,698,6931,693,1791,708,0501,703,8051,375,3141,373,9151,361,199475,85700461,33991,79175,01774,99754,8610000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
1,630
1,271
1,865
2,967
1,423
336
0
0
0
0
0
0
0
00000003361,4232,9671,8651,2711,63000000000000
       Other Liabilities 
0
0
0
0
8,210
10,296
1,388
3,527
2,797
9,399
13,469
9,520
10,118
11,853
26,249
22,069
26,829
28,631
28,226
26,643
0
13,326
0
0
0013,326026,64328,22628,63126,82922,06926,24911,85310,1189,52013,4699,3992,7973,5271,38810,2968,2100000
       Deferred Long Term Liability 
0
0
0
0
1,800
6,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006,5001,8000000
> Total Stockholder Equity
-61,427
0
0
-163,986
252,141
-316,119
459,758
408,454
380,715
265,759
163,756
57,906
-395,294
-464,294
-743,397
-870,414
-1,040,996
-1,025,532
-1,138,417
-1,254,617
-1,225,665
-1,362,023
-1,207,543
-1,354,257
-1,354,257-1,207,543-1,362,023-1,225,665-1,254,617-1,138,417-1,025,532-1,040,996-870,414-743,397-464,294-395,29457,906163,756265,759380,715408,454459,758-316,119252,141-163,98600-61,427
   Common Stock
0
0
0
6,594
100
9,949
117
124
124
125
125
125
152
153
153
154
154
154
156
157
167
168
180
181
1811801681671571561541541541531531521251251251241241179,9491006,594000
   Retained Earnings Total Equity000-2,057,455-1,918,149-1,780,558-1,643,219-1,633,363-1,436,966-1,289,789-1,133,854-1,037,506-888,75500000000000
   Accumulated Other Comprehensive Income 
0
0
0
-231
0
0
152
254
726
858
461
192
-57
36
19
-132
-383
-427
-348
-328
-12
63
34
31
313463-12-328-348-427-383-1321936-5719246185872625415200-231000
   Capital Surplus 
0
0
0
0
0
0
826,062
848,107
986,746
0
0
1,021,344
767,117
799,679
821,220
841,530
867,596
892,960
917,333
938,703
1,106,635
0
0
0
0001,106,635938,703917,333892,960867,596841,530821,220799,679767,1171,021,34400986,746848,107826,062000000
   Treasury Stock000-275,000-275,000-275,000-275,000-275,000-275,000-275,000-130,308-125,000-75,00000-75,00000000000
   Other Stockholders Equity 
0
0
0
109
486,774
-175
826,062
845,864
911,746
917,691
931,944
946,344
642,117
669,371
546,220
566,530
592,596
617,960
642,333
663,703
831,635
853,100
1,184,596
1,206,032
1,206,0321,184,596853,100831,635663,703642,333617,960592,596566,530546,220669,371642,117946,344931,944917,691911,746845,864826,062-175486,774109000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue9,303
Cost of Revenue-2,446
Gross Profit6,8576,857
 
Operating Income (+$)
Gross Profit6,857
Operating Expense-606,301
Operating Income-607,370-599,444
 
Operating Expense (+$)
Research Development455,711
Selling General Administrative150,590
Selling And Marketing Expenses0
Operating Expense606,301606,301
 
Net Interest Income (+$)
Interest Income18,038
Interest Expense-81,289
Other Finance Cost-0
Net Interest Income-63,251
 
Pretax Income (+$)
Operating Income-607,370
Net Interest Income-63,251
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-653,251-616,814
EBIT - interestExpense = -662,425
-571,692
-561,913
Interest Expense81,289
Earnings Before Interest and Taxes (EBIT)-581,136-571,962
Earnings Before Interest and Taxes (EBITDA)-574,642
 
After tax Income (+$)
Income Before Tax-653,251
Tax Provision-0
Net Income From Continuing Ops-653,251-653,251
Net Income-643,202
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses608,747
Total Other Income/Expenses Net9,44463,251
 

Technical Analysis of Bridgebio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bridgebio. The general trend of Bridgebio is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bridgebio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BridgeBio Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 32.54 < 33.14 < 40.65.

The bearish price targets are: 26.82 > 26.14 > 23.67.

Tweet this
BridgeBio Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BridgeBio Pharma Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BridgeBio Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BridgeBio Pharma Inc. The current macd is -0.92214057.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bridgebio price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Bridgebio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Bridgebio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BridgeBio Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartBridgeBio Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BridgeBio Pharma Inc. The current adx is 18.80.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Bridgebio shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
BridgeBio Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BridgeBio Pharma Inc. The current sar is 27.39.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
BridgeBio Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BridgeBio Pharma Inc. The current rsi is 50.75. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
BridgeBio Pharma Inc Daily Relative Strength Index (RSI) ChartBridgeBio Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BridgeBio Pharma Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bridgebio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BridgeBio Pharma Inc Daily Stochastic Oscillator ChartBridgeBio Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BridgeBio Pharma Inc. The current cci is 62.69.

BridgeBio Pharma Inc Daily Commodity Channel Index (CCI) ChartBridgeBio Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BridgeBio Pharma Inc. The current cmo is 19.31.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BridgeBio Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartBridgeBio Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BridgeBio Pharma Inc. The current willr is -7.02947846.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
BridgeBio Pharma Inc Daily Williams %R ChartBridgeBio Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BridgeBio Pharma Inc.

BridgeBio Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BridgeBio Pharma Inc. The current atr is 1.53802735.

BridgeBio Pharma Inc Daily Average True Range (ATR) ChartBridgeBio Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BridgeBio Pharma Inc. The current obv is 78,661,091.

BridgeBio Pharma Inc Daily On-Balance Volume (OBV) ChartBridgeBio Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BridgeBio Pharma Inc. The current mfi is 61.52.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
BridgeBio Pharma Inc Daily Money Flow Index (MFI) ChartBridgeBio Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BridgeBio Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

BridgeBio Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BridgeBio Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.752
Ma 20Greater thanMa 5029.555
Ma 50Greater thanMa 10033.016
Ma 100Greater thanMa 20033.558
OpenGreater thanClose30.780
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bridgebio with someone you think should read this too:
  • Are you bullish or bearish on Bridgebio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bridgebio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BridgeBio Pharma Inc

I send you an email if I find something interesting about BridgeBio Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about BridgeBio Pharma Inc.

Receive notifications about BridgeBio Pharma Inc in your mailbox!